The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 26, 2022
Filed:
Aug. 10, 2017
Fuso Pharmaceutical Industries, Ltd., Osaka, JP;
National University Corporation Hokkaido University, Hokkaido, JP;
Satoru Konnai, Hokkaido, JP;
Kazuhiko Ohashi, Hokkaido, JP;
Shiro Murata, Hokkaido, JP;
Tomohiro Okagawa, Hokkaido, JP;
Asami Nishimori, Hokkaido, JP;
Naoya Maekawa, Hokkaido, JP;
Yasuhiko Suzuki, Hokkaido, JP;
Chie Nakajima, Hokkaido, JP;
Fuso Pharmaceutical Industries, Ltd., Osaka, JP;
National University Corporation Hokkaido University, Sapporoshi, JP;
Abstract
The present invention provides an anti-PD-L1 antibody capable of repeated administration even to animals other than rat. An anti-PD-L1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLYSENQKDY (SEQ ID NO: 37), CDR2 having the amino acid sequence of WAT and CDR3 having the amino acid sequence of GQYLVYPFT (SEQ ID NO: 38) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GYTFTSNF (SEQ ID NO: 39), CDR2 having the amino acid sequence of IYPEYGNT (SEQ ID NO: 40) and CDR3 having the amino acid sequence of ASEEAVISLVY (SEQ ID NO: 41) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-PD-L1 antibody as an active ingredient. A method for preparing the above anti-PD-L1 antibody is also provided.